VBWG
Data alert

New data on the anti-ischemic effects of ACE inhibition

During the past decade, results from a number of clinical trials have revolutionized the way clinicians treat CHD and CAD. The SOLVD and SAVE trials laid the foundation for the current understanding of CVD as a consequence of endothelial dysfunction and of the importance of ACE as a therapeutic target. These significant results made an immediate impact on patient management. Subsequent studies have built on this knowledge and the details of how ACE inhibition at the tissue level improves endothelial function are being revealed.





DA1.ppt

Download DA1.ppt (5 slides - 0.2MB)

Slide 1 Slide 2 Slide 3 Slide 4 Slide 5
Data_Alert.pdf (0.2MB)Data_Alert.pdf (0.2MB)


ACECADCHDcliniciansinhibitionischemicrevolutionizedway

Related at vwbg.org

Vascular Biology in Clinical Practice © Vol. 7, No. 1

ACE Inhibition in CAD Patients: Expanding the Reach of Cardioprotection

This monograph, ACE Inhibition in CAD Patients: Expanding the Reach of Cardioprotection , which is being offered as part of a series of continuing medical education activities from the University of Florida College of Medicine.

Vascular Biology in Clinical Practice © Vol. 6, No. 3

A HOPE FOR PEACE? Update on the role of ACE inhibition in CAD patients

This monograph, A HOPE for PEACE? Update on the role of ACE inhibition in CAD patients , is offered as part of a series of continuing medical education activities from the University of Florida College of Medicine.

Decrease in PAI-1 antigen is greater with ACE inhibition

Plasminogen activator inhibitor-1 (PAI-1) is a known risk factor for cardiovascular (CV) disease and myocardial infarction (MI).
More related